What You Should Know:
– Briya, a health technology company redefining medical research launches Briya AIRE™, the world’s first clinical-grade AI research assistant built to accelerate biomedical and clinical decision-making.
– Designed to “think” in the language of medicine, clinical research, and epidemiology, AIRE aims to transform months of manual data analysis into actionable insights in minutes, enabling faster, cost-effective discovery across biopharma and academic research sectors.
AIRE Insights: Optimizing Research and Treatment Priorities
Unlike traditional AI tools that merely curate and synthesize data, Briya AIRE acts as a virtual epidemiologist and data analyst. It is built to help researchers ask better questions and generate answers faster by designing patient cohorts, testing hypotheses, refining study criteria, and identifying data patterns that might otherwise be missed. By guiding researchers through these critical steps, Briya AIRE helps optimize study design and accelerate discoveries that can impact drug development and patient care.
Briya AIRE simplifies AI for science through several key functionalities:
- Plain Language Queries: Researchers can ask questions in everyday language, which AIRE translates into precise medical and research terms, eliminating the need for coding expertise.
- Unified Data View: AIRE interfaces with existing clinical or hospital records, research databases, and free-text doctors’ notes, pulling all information into one comprehensive view.
- Evidence-Based Suggestions: Automatic suggestions are grounded in peer-reviewed science, drawing from published medical studies and proven research methods, thus eliminating repetitive data preparation.
- Secure Infrastructure: AIRE is built on Briya’s secure infrastructure and meets U.S. and European privacy standards, ensuring patient data remains protected.
Briya AIRE is currently being used by global academic medical centers, biopharma organizations, and research institutions across a range of disciplines and therapeutic indications. Its advanced natural language processing (NLP) and analytical capabilities have already demonstrated potential to facilitate earlier diagnosis, enabling timely interventions for at-risk patients.
“Life-saving research should never be delayed because researchers and physicians are expected to become program coders,” said David Lazerson, Co-founder and CEO of Briya. “Unlike general-purpose AI tools, Briya AIRE has been built specifically for clinical and biomedical researchers to ask questions in plain language, instantly translated into epidemiologically valid and scientifically precise requests. The outcome is an accelerated research journey.”
